Malaria vaccines and their potential role in the elimination of malaria

Malaria Journal

Volumn 7, Issue SUPPL. 1, 2008, Pages

  Targett, Geoffrey A ^a   Greenwood, Brian M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; PARASITE ANTIGEN; PFS 230 ANTIGEN; PFS 25 ANTIGEN; PFS 28 ANTIGEN; PFS 48 45 ANTIGEN; RESA ANTIGEN; THROMBOSPONDIN RELATED ANONYMOUS PROTEIN; UNCLASSIFIED DRUG; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TRANSMISSION BLOCKING VACCINE BASED ON PFS25; TRANSMISSION-BLOCKING VACCINE BASED ON PFS25;

CLINICAL TRIAL; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG EFFICACY; ERYTHROCYTE LIFESPAN; HUMAN; LIFE CYCLE; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW; SPOROZOITE; VACCINATION; ANIMAL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; PARASITOLOGY; PLASMODIUM;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 57649135086     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-S1-S10     Document Type: Review

References (69)

1. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. CA Guerra PW Gikandi AJ Tatem AM Noor DL Smith SI Hay RW Snow, PLoS Med 2008 5 e38 18303939 10.1371/journal.pmed.0050038
2. Neglect of Plasmodium vivax malaria. JK Baird, Trends Parasitol 2007 23 533 539 17933585
3. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. KI Barnes DN Durrheim F Little A Jackson U Mehta E Allen SS Dlamini J Tsoka B Bredenkamp DJ Mthembu NJ White BL Sharp, PLoS Med 2005 2 e330 16187798 10.1371/journal.pmed.0020330
4. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. A Bhattarai AS Ali SP Kachur A Martensson AK Abbas R Khatib AW Al-Mafazy M Ramsan G Rotllant JF Gerstenmaier F Molteni S Abdulla SM Montgomery A Kaneko A Björkman, PLoS Med 2007 4 e309 17988171 10.1371/journal.pmed.0040309
5. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. PM Nyarango T Gebremeskel G Mebrahtu J Mufunda U Abdulmumini A Ogbamariam A Kosia A Gebremichael D Gunawardena Y Ghebrat Y Okbaldet, Malar J 2006 5 33 16635265 10.1186/1475-2875-5-33
6. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. SJ Ceesay C Casals-Pascual J Erskine SE Anya NO Duah AJ Fulford SS Sesay I Abubakar S Dunyo O Sey A Palmer M Fofana T Corrah KA Bojang HC Whittle BM Greenwood DJ Conway, Lancet 2008 372 1545 1554 10.1016/S0140-6736(08)61654-2 18984187
7. The decline in paediatric malaria admissions on the coast of Kenya. EA Okiro SI Hay PW Gikandi SK Sharif AM Noor N Peshu K Marsh RW Snow, Malar J 2007 6 151 18005422 10.1186/1475-2875-6-151
8. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. WP O'Meara P Bejon TW Mwangi EA Okiro N Peshu RW Snow CR Newton K Marsh, Lancet 2008 372 1555 1562 10.1016/S0140-6736(08)61655-4 18984188
9. From malaria control to elimination: implications for the research agenda. BM Greenwood, Trends Parasitol 2008 24 449 454 10.1016/j.pt.2008.07.002 18760671
10. A new global malaria eradication strategy. R Feachem O Sabot, Lancet 2008 371 1633 1635 10.1016/S0140-6736(08)60424-9 18374409
11. Malaria eradication on islands. A Kaneko G Taleo M Kalkoa S Yamar T Kobayakawa A Bjorkman, Lancet 2000 356 1560 1564 10.1016/S0140-6736(00)03127-5 11075770
12. The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. C Drakeley C Sutherland JT Bousema RW Sauerwein GA Targett, Trends Parasitol 2006 22 424 430 10.1016/j.pt.2006.07.001 16846756
13. Dynamics of gametocytes among Plasmodium falciparum clones in natural infections in an area of highly seasonal transmission. A Abdel-Wahab AM Abdel-Muhsin E Ali S Suleiman S Ahmed D Walliker HA Babiker, J Infect Dis 2002 185 1838 1842 10.1086/340638 12085337
14. Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania. CJ Drakeley NI Akim RW Sauerwein BM Greenwood GA Targett, Trans R Soc Trop Med Hyg 2000 94 472 476 10.1016/S0035-9203(00)90056-7 11132369
15. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. P Schneider JT Bousema LC Gouagna S Otieno M van de Vegte-Bolmer SA Omar RW Sauerwein, Am J Trop Med Hyg 2007 76 470 474 17360869
16. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. JT Bousema P Schneider LC Gouagna CJ Drakeley A Tostmann R Houben JI Githure R Ord CJ Sutherland SA Omar RW Sauerwein, J Infect Dis 2006 193 1151 1159 10.1086/503051 16544256
17. Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. SA Shekalaghe JT Bousema KK Kunei P Lushino A Masokoto LR Wolters S Mwakalinga FW Mosha RW Sauerwein CJ Drakeley, Trop Med Int Health 2007 12 547 553 17445146
18. Heterogeneities in the transmission of infectious agents: implications for the design of control programs. ME Woolhouse C Dye JF Etard T Smith JD Charlwood GP Garnett P Hagan JL Hii PD Ndhlovu RJ Quinnell, Proc Natl Acad Sci USA 1997 94 338 342 8990210 10.1073/pnas.94.1.338
19. Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. LJ Kasehagen I Mueller DT McNamara MJ Bockarie B Kiniboro L Rare K Lorry W Kastens JC Reeder JW Kazura PA Zimmerman, Am J Trop Med Hyg 2006 75 588 596 17038678
20. Malaria Vaccine Technology Roadmap. http://www.malariavaccineroadmap.net
21. Immunology of malaria infections - implications for the design and development of malaria vaccines. MM Stevenson F Zavala, Parasite Immunol 2006 28 1 60 10.1111/j.1365-3024.2006.00797.x 16438670
22. Malaria vaccines 1985-2005: a full circle? GA Targett, Trends Parasitol 2005 21 499 503 10.1016/j.pt.2005.08.018 16137925
23. Sanaria. http://www.sanaria.com
24. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. AK Mueller M Labaied SH Kappe K Matuschewski, Nature 2005 433 164 167 10.1038/nature03188 15580261
25. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. M Labaied A Harupa RF Dumpit I Coppens SA Mikolajczak SH Kappe, Infect Immun 2007 75 3758 3768 17517871 10.1128/IAI.00225-07
26. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. O Jobe J Lumsden AK Mueller J Williams H Silva-Rivera SH Kappe RJ Schwenk K Matuschewski U Krzych, J Infect Dis 2007 196 599 607 10.1086/519743 17624847
27. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. AK Mueller M Deckert K Heiss K Goetz K Matuschewski D Schluter, Am J Pathol 2007 171 107 115 17591958 10.2353/ajpath.2007.060792
28. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. AS Tarun RF Dumpit N Camargo M Labaied P Liu A Takagi R Wang SH Kappe, J Infect Dis 2007 196 608 616 10.1086/519742 17624848
29. Assessment of cellular immune responses in infants participating in a RTS, S/ASO2D phase I/IIB trial in Mozambique. A Barbosa D Naniche MN Manaca JJ Aponte I Mandomando P Aide M Renom J Sacarlal WR Ballou P Moris J Cohen F Dubovsky J Millman PL Alonso, Am J Trop Med Hyg 2007 77 Abstr 9 2 3
30. A randomized, observer-blind trial to compare safety and immunogenicity of two adjuvanted RTS, S anti-malaria vaccine candidates in Gabonese children. B Lell S Agnandji I von Glasenapp S Oyakhiromen S Haertle PG Kremsner I Ramboer M Lievens WR Ballou J Vekemans M-C Dubois M-A Demoitie J Cohen T Villafana T Carter T Petersen, Am J Trop Med Hyg 2007 77 Abstr 10 3 17620623
31. Impact of RTS, S/ASO2A and RTS, s/ASO1B on multiplicity of infections and CSP T-cell epitopes of Plasmodium falciparum in adults participating in a malaria vaccine clinical trial. SB Anyona CW Hunja CM Kifude ME Polhemus DG Heppner A Leach M Lievens WR Ballou J Cohen C Sutherland, Am J Trop Med Hyg 2007 77 Abstr 578 166
32. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. KE Kester DA McKinney N Tornieporth CF Ockenhouse DG Heppner T Hall U Krzych M Delchambre G Voss MG Dowler J Palensky J Wittes J Cohen WR Ballou RTS S Malaria Vaccine Evaluation Group, J Infect Dis 2001 183 640 647 10.1086/318534 11170991
33. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. KA Bojang PJ Milligan M Pinder L Vigneron A Alloueche KE Kester WR Ballou DJ Conway WH Reece P Gothard L Yamuah M Delchambre G Voss BM Greenwood A Hill KP McAdam N Tornieporth JD Cohen T Doherty RTS S Malaria Vaccine Trial Team, Lancet 2001 358 1927 1934 10.1016/S0140-6736(01)06957-4 11747915
34. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. PL Alonso J Sacarlal JJ Aponte A Leach E Macete P Aide B Sigauque J Milman I Mandomando Q Bassat C Guinovart M Espasa S Corachan M Lievens MM Navia MC Dubois C Menendez F Dubovsky J Cohen R Thompson WR Ballou, Lancet 2005 366 2012 2018 10.1016/S0140-6736(05)67669-6 16338450
35. Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. JJ Aponte P Aide M Renom I Mandomando Q Bassat J Sacarlal MN Manaca S Lafuente A Barbosa A Leach M Lievens J Vekemans B Sigauque MC Dubois MA Demoitié M Sillman B Savarese JG McNeil E Macete WR Ballou J Cohen PL Alonso, Lancet 2007 370 1543 1551 10.1016/S0140-6736(07)61542-6 17949807
36. Pre-erythrocytic malaria vaccines: towards greater efficacy. AV Hill, Nat Rev Immunol 2006 6 21 32 10.1038/nri1746 16493425
37. Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria. M Walther, Expert Rev Vaccines 2006 5 81 93 10.1586/14760584.5.1.81 16451110
38. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. J Hu Z Chen J Gu M Wan Q Shen MP Kieny J He Z Li Q Zhang ZH Reed Y Zhu W Li Y Cao L Qu Z Cao Q Wang H Liu X Pan X Huang D Zhang X Xue W Pan, PLoS ONE 2008 3 e1952 18398475 10.1371/journal.pone.0001952
39. Malaria: progress, perils, and prospects for eradication. BM Greenwood DA Fidock DE Kyle SH Kappe PL Alonso FH Collins PE Duffy, J Clin Invest 2008 118 1266 1276 18382739 10.1172/JCI33996
40. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. A Dicko I Sagara RD Ellis K Miura O Guindo B Kamate M Sogoba MB Niambele M Sissoko M Baby A Dolo GE Mullen MP Fay M Pierce DA Diallo A Saul LH Miller OK Doumbo, PLoS ONE 2008 3 e1563 18270560 10.1371/journal.pone.0001563
41. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. E Malkin CA Long AW Stowers L Zou S Singh NJ MacDonald DL Narum AP Miles AC Orcutt O Muratova SE Moretz H Zhou A Diouf M Fay E Tierney P Leese S Mahanty LH Miller A Saul LB Martin, PLoS Clin Trials 2007 2 e12 17415408 10.1371/journal.pctr.0020012
42. High road, low road? Choices and challenges on the pathway to a malaria vaccine. T Richie, Parasitology 2006 133 Suppl S1 13 144
43. Apical membrane antigen 1: a malaria vaccine candidate in review. EJ Remarque BW Faber CH Kocken AW Thomas, Trends Parasitol 2008 24 74 84 10.1016/j.pt.2007.12.002 18226584
44. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. P Druilhe F Spertini D Soesoe G Corradin P Mejia S Singh R Audran A Bouzidi C Oeuvray C Roussilhon, PLoS Med 2005 2 e344 16262450 10.1371/journal.pmed.0020344
45. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. B Genton I Betuela I Felger F Al-Yaman RF Anders A Saul L Rare M Baisor K Lorry GV Brown D Pye DO Irving TA Smith HP Beck MP Alpers, J Infect Dis 2002 185 820 827 10.1086/339342 11920300
46. Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions. J Baum AG Maier RT Good KM Simpson AF Cowman, PLoS Pathog 2005 1 e37 16362075 10.1371/journal.ppat.0010037
47. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. SL Takala D Coulibaly MA Thera A Dicko DL Smith AB Guindo AK Kone K Traore A Ouattara AA Djimde PS Sehdev KE Lyke DA Diallo OK Doumbo CV Plowe, PLoS Med 2007 4 e93 17355170 10.1371/journal.pmed.0040093
48. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. YS Devi P Mukherjee SS Yazdani AR Shakri S Mazumdar S Pandey CE Chitnis VS Chauhan, Vaccine 2007 25 5166 5174 10.1016/j.vaccine.2007.04.080 17544179
49. Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? CE Cavasini LC Mattos AA Couto CR Bonini-Domingos SH Valencia WC Neiras RT Alves AR Rossit L Castilho RL Machado, Trans R Soc Trop Med Hyg 2007 101 1042 1044 10.1016/j.trstmh.2007.04.011 17604067
50. Plasmodium in the placenta: parasites, parity, protection, prevention and possibly preeclampsia. PE Duffy, Parasitology 2007 134 1877 1881 10.1017/S0031182007000170 17958923
51. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. L Schofield MC Hewitt K Evans MA Siomos PH Seeberger, Nature 2002 418 785 789 10.1038/nature00937 12181569
52. Transmission blocking malaria vaccines. R Carter, Vaccine 2001 19 2309 2314 10.1016/S0264-410X(00)00521-1 11257353
53. Efficacy model for mosquito stage transmission blocking vaccines for malaria. A Saul, Parasitology 2008 135 1497 1506 10.1017/S0031182008000280 18257944
54. Mosquito stage, transmission blocking vaccines for malaria. A Saul, Curr Opin Infect Dis 2007 20 476 481 10.1097/QCO.0b013e3282a95e12 17762780
55. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. K Miura DB Keister OV Muratova J Sattabongkot CA Long A Saul, Malar J 2007 6 107 17686163 10.1186/1475-2875-6-107
56. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. J Kubler-Kielb F Majadly Y Wu DL Narum C Guo LH Miller J Shiloach JB Robbins R Schneerson, Proc Natl Acad Sci USA 2007 104 293 298 17190797 10.1073/pnas.0609885104
57. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. EM Malkin AP Durbin DJ Diemert J Sattabongkot Y Wu K Miura CA Long L Lambert AP Miles J Wang A Stowers LH Miller A Saul, Vaccine 2005 23 3131 3138 10.1016/j.vaccine.2004.12.019 15837212
58. Murine model for assessment of Plasmodium falciparum transmission- blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. G Mlambo J Maciel N Kumar, Infect Immun 2008 76 2018 2024 18316385 10.1128/IAI.01409-07
59. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. S Ramjanee JS Robertson B Franke-Fayard R Sinha AP Waters CJ Janse Y Wu AM Blagborough A Saul RE Sinden, Vaccine 2007 25 886 894 10.1016/j.vaccine.2006.09.035 17049690
60. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. N Outchkourov A Vermunt J Jansen A Kaan W Roeffen K Teelen E Lasonder A Braks M van de Vegte-Bolmer LY Qiu R Sauerwein HG Stunnenberg, J Biol Chem 2007 282 17148 17156 10.1074/jbc.M700948200 17426022
61. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. NS Outchkourov W Roeffen A Kaan J Jansen A Luty D Schuiffel GJ van Gemert M van de Vegte-Bolmer RW Sauerwein HG Stunnenberg, Proc Natl Acad Sci USA 2008 105 4301 4305 18332422 10.1073/pnas.0800459105
62. L Molineaux G Gramiccio, The Garki project: research on the epidemiology and control of malaria in the Sudan savanna of West Africa WHO Geneva 1980
63. The primary antibody response of malaria patients to Plasmodium falciparum sexual stage antigens which are potential transmission blocking vaccine candidates. CS Ong KY Zhang SJ Eida PM Graves C Dow M Looker NC Rogers PL Chiodini GA Targett, Parasite Immunol 1990 12 447 456 10.1111/j.1365-3024. 1990.tb00980.x 2255558
64. Sexual-stage antibody responses to P. falciparum in endemic populations. JT Bousema CJ Drakeley RW Sauerwein, Curr Mol Med 2006 6 223 229 10.2174/156652406776055140 16515512
65. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. JS Peiris S Premawansa MB Ranawaka PV Udagama YD Munasinghe MV Nanayakkara CP Gamage R Carter PH David KN Mendis, Am J Trop Med Hyg 1988 39 26 32 3041855
66. Is immunity to malaria really short-lived? P Deloron C Chougnet, Parasitol Today 1992 8 375 378 10.1016/0169-4758(92)90174-Z 15463545
67. Does malaria suffer from lack of memory? SS Struik EM Riley, Immunol Rev 2004 201 268 290 10.1111/j.0105-2896.2004.00181.x 15361247
68. Determination of the processes driving the acquisition of immunity to malaria using a mathematical transmission model. JA Filipe EM Riley CJ Drakeley CJ Sutherland AC Ghani, PLoS Comput Biol 2007 3 e255 18166074 10.1371/journal.pcbi.0030255
69. Human immunity and the design of multi-component, single target vaccines. A Saul MP Fay, PLoS ONE 2007 2 e850 17786221 10.1371/journal.pone.0000850